Cervene in acute ischemic stroke: Results of a double-blind, placebo-controlled, dose-comparison study

Journal of Stroke and Cerebrovascular Diseases

Volumn 8, Issue 4, 1999, Pages 224-230

  Clark, Wayne ^a,b,c   Ertag, William ^a,b,c   Orecchio, Edward ^a,b,c   Raps, Eric ^a,b,c  

^a Oregon Stroke Center   (United States)

^b Toledo Clinic ^*

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Nalmefene; Opiate antagonist; Stroke; Therapy

Indexed keywords

EID: 0001223098     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3057(99)80071-8     Document Type: Article

References (37)

1. Rothman S., and Olney J. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 19 (1986) 105-111
2. Olney J.W. Excitotoxins: An overview. In: Fuxe K., Roberts P.J., and Schwarcz R. (Eds). Exitcotoxins (1983), McMillan Press, London 92-96
3. Faden A.I. Neuropeptides and central nervous system injury. Arch Neurol 43 (1986) 501-504
4. Zivin J.A., and Choi D.W. Stroke therapy. Sci Am 265 (1991) 56-63
5. (abstr). Albers G., Clark W., Atkinson R., et al. Dose escalation study of the NMDA glycine-site antagonist ACEA 1021 in acute ischemic stroke. Stroke 28 (1997) 271
6. (abstr). Grotta J., Hantson L., and Wessel T. The efficacy and safety of lubeluzole in patients with acute ischemic stroke. Stroke 28 (1997) 271
7. (abstr). Edwards K for the CNS 1102-008 Study Group. Cerestat in the treatment of acute ischemic stroke: Results of a phase II trial. Neurology 46 (1996) 424
8. Grotta J., Clark W., Coull B., et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: Results of a Phase II a randomized trial. Stroke 26 (1995) 602-605
9. Albers G., Atkinson R., Kelley R., et al. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26 (1995) 254-258
10. (abstr). Davis S for the Assist Collaborative Group. Acute stroke studies involving selfotel treatment. Stroke 28 (1997) 271
11. Faden A.I. Role of opiate antagonists in the treatment of stroke. In: Weinstein P.R., and Faden A.I. (Eds). Protection of the brain from ischemia (1990), Williams and Wilkins, Baltimore 265-271
12. Krumins S.A., and Faden A.I. Traumatic injury alters opiate receptor binding in spinal cord. Ann Neurol 19 (1986) 498-501
13. Herman B.H., and Goldstein A. Antinociception and paralysis induced by intrathecal dynorphin. Am J Pharmacol Exp Ther 232 (1985) 27-32
14. Faden A.I., Molineaux C.J., Rosenberger J.G., et al. Increased dynorphin immunoreactivity in spinal cord after traumatic injury. Reg Pept 11 (1985) 35-41
15. Scavini S., Rozza A., Bo P., et al. K-opioid receptor changes and neurophysiological alterations during cerebral ischemia in rabbits. Stroke 21 (1990) 943-947
16. Harini R.J., Supra E.L., Roberts J.P., et al. Effect of naloxone on cerebral perfusion and cardiac performance during experimental cerebral ischemia. J Neurosurg 64 (1986) 780-786
17. 5)-enkephalinamide, and naloxone on cortical blood flow and cerebral blood volume in experimental brain ischemia in anesthetized cats. J Cereb Blood Flow Metab 6 (1986) 553-558
18. Namba S., Nishigaki S., Fujiwara N., et al. Opiateantagonist reversal of neurological deficits: Experimental and clinical studies. Jpn J Psych Neurol (1986) 40
19. Fallis R.J., Fisher M., and Lobo R.A. A double blind trial of naloxone in the treatment of acute stroke. Stroke 15 (1984) 627-629
20. Perraro F., Tosocini G., Pertoldi F., et al. Double-blind placebo controlled trial of naloxone on motor deficits in acute cerebrovascular disease. Lancet 1 (1984) 915-918
21. Hahn E.F., Fishman J., and Heilman R.D. Narcotic antagonists.4.carbon-6 deratives of N-substituted noroxymorphones as narcotic antagonists. J Med Chem 18 (1975) 259-262
22. (abstr). Michel M.E., Bolger G., and Weissman B.A. Binding of a new opiate antagonists, nalmefene, to rat brain membranes. Pharmacologist 26 (1984) 201
23. Yum S.W., and Faden A.I. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK801 and the opiate receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol 47 (1990) 277-281
24. Faden A.I., Shirane R., Chang L.H., et al. Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats. J Pharmacol Exp Ther 255 (1990) 451-460
25. Graham S.H., Shimizu H., Newman A., et al. Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia. Brain Res 632 (1993) 346-350
26. Vink S.W., Mcintosh T.K., Rhomhanzi R., et al. Opiate antagonist nalmefene improves intracellular free Mg2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats. J Neurosci 10 (1990) 3524-3530
27. Nalmefene hydrochloride injection for CNS trauma and ichemia. Investigator's Brochure, IVX-B-116 (September, 1995)
28. Clark W., Coull B., Karukin M., et al. Randomized trial of Cervene, a k receptor-selective opioid antagonist, in acute ischemic stroke. J Stroke Cerebrovasc Dis 6 (1996) 35-40
29. Mahoney F., and Barthel D. Functional evaluation: Barthel index. Md State Med J 14 (1965) 61-65
30. Jennett B., and Bond M. Assessment of outcome after severe brain damage. A practical scale. Lancet I (1975) 480-484
31. Brott T., Adams H., and Olinger C. Measurements of acute cerebral infarction: A clinical examination scale. Stroke 20 (1989) 864-870
32. Lyden P., Brott T., Tilley B., et al. Improved reliability of NIH stroke scale using video training. Stroke 25 (1990) 2220-2226
33. Adams H., Bendixen B., Kappelle J., et al. Classification of subtype of acute ischemic stroke. Stroke 24 (1993) 35-41
34. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
35. Clark W.M., and Coull BM for the CGS19755 Study Group. Randomized trial of CGS19755, a glutamate antagonist, in acute ischemic stroke treatment. Neurology 44 (1994) A270
36. Albers G.W., Atkinson R.P., Kelley R.E., et al., Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with an acute stroke. Stroke 26 (1995) 254-258
37. Lesko L for the Cerestat Stroke Study Group. A pivotal phase III efficacy and safety study of Cerestat in acute stroke patients. Stroke 28 (1997) 232-238